Cardiac Resynchronization Therapy Market Size, Share, Growth Analysis, By Product (Cardiac Resynchronization Therapy Defibrillators, Cardiac Resynchronization Therapy Pacemakers), By Application (Intraventricular Desynchrony, Interventricular (V-V) Desynchrony), By End User, By Region - Industry Forecast 2024-2031

Cardiac Resynchronization Therapy Market Drivers:

Increasing Prevalence of Cardiovascular Diseases

• Approximately half of all mortality from cardiovascular diseases are caused by sudden cardiac death, despite advancements in prevention and therapy. Sudden cardiac death is still a major cause of death. The demand for cardiac resynchronization therapy devices is anticipated to rise as a result of the rising prevalence of heart illnesses and their risk factors. Heart failure is one of the leading causes of death in the world.

Rising Sedentary Lifestyle 

• Physical inactivity is a major public health concern because it is connected to the second-highest number of deaths in the U.S., after smoking. Morbid obesity and numerous other chronic conditions, including heart issues and diabetes, can be brought on by physical inactivity. It has frequently been noted that prolonged periods of inactivity worsen the symptoms of CVD in diabetic and atherosclerotic patients who are otherwise physically active. Cardiovascular diseases like angina, myocardial infarction, and stroke are major effects of this lifestyle.

Cardiac Resynchronization Therapy Market Restraint:

Product Recall

• Boston Scientific Corporation started the INGENIO family of pacemakers and CRT-Ps recall in June 2022. ADVANTIO DR EL, INGENIO DR EL, and VITALIO DR EL are a few of them. Between November 2016 and August 2022, the recalled devices were distributed after being produced between September 2016 and December 2018. In the United States, some 48,000 gadgets were recalled. The possibility of the gadget entering safety mode led to the recall.